Glaucoma, Primary Open Angle
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Due to opticin's protein profile in the eye, we have also screened OPTC for mutations in individuals with primary open-angle glaucoma (POAG), normal-tension glaucoma (NTG) or AMD.
|
12019215 |
2002 |
Low Tension Glaucoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Due to opticin's protein profile in the eye, we have also screened OPTC for mutations in individuals with primary open-angle glaucoma (POAG), normal-tension glaucoma (NTG) or AMD.
|
12019215 |
2002 |
Age related macular degeneration
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Due to opticin's protein profile in the eye, we have also screened OPTC for mutations in individuals with primary open-angle glaucoma (POAG), normal-tension glaucoma (NTG) or AMD.
|
12019215 |
2002 |
Glaucoma, Primary Open Angle
|
0.030 |
Biomarker
|
disease |
BEFREE |
Our study suggests OPTC as a candidate gene for POAG.
|
17359525 |
2007 |
Glaucoma, Primary Open Angle
|
0.030 |
Biomarker
|
disease |
BEFREE |
This study was designed to evaluate the involvement of the CYP1B1, MYOC, OPTN, and OPTC genes in the etiology of adult-onset primary open-angle glaucoma (POAG) found in 251 Indian patients.
|
17563717 |
2007 |
Severe myopia
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Five changes were detected in opticin, Thr177Arg, Arg229His, Arg325Trp, Gly329Ser, and Arg330His, and all but one (Arg229His) were shown to cosegregate with high myopia in families with incomplete penetrance.
|
17117407 |
2007 |
Glaucoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Given its expression in the optic nerve, it is likely a mutation in the OPTC gene is also involved in initiating glaucoma.
|
17563717 |
2007 |
Glaucoma, Open-Angle
|
0.010 |
Biomarker
|
disease |
LHGDN |
Evaluation of the OPTC gene in primary open angle glaucoma: functional significance of a silent change.
|
17359525 |
2007 |
Degenerative polyarthritis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Identification of opticin, a member of the small leucine-rich repeat proteoglycan family, in human articular tissues: a novel target for MMP-13 in osteoarthritis.
|
18164633 |
2008 |
Severe myopia
|
0.020 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to test whether mutations in the two members of the class III SLRPs, opticin (OPTC) and dermatan sulfate proteoglycan 3 (EPYC), are responsible for high myopia.
|
19844586 |
2009 |
Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
In addition, the CL20i4-EF1alpha-hgamma(c)OPT vector has not caused any tumors in transplanted mice.
|
20457870 |
2010 |
Clostridium; difficile (disorder)
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin.
|
20724385 |
2010 |
Chronic small plaque psoriasis
|
0.020 |
Biomarker
|
disease |
BEFREE |
A Phase 3 withdrawal/re-treatment study (NCT01186744; OPT Retreatment) showed tofacitinib re-treatment was effective in patients with chronic plaque psoriasis.
|
27600367 |
2017 |
Psoriasis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Selected baseline characteristics or early improvement in Psoriasis Area and Severity Index (PASI) in the phase 3 tofacitinib study OPT 1 (NCT01276639) were evaluated as predictors for a clinical response (75% improvement in PASI [PASI75]) at week 16.
|
27538247 |
2017 |
Degenerative polyarthritis
|
0.020 |
Biomarker
|
disease |
BEFREE |
In vivo effect of opticin deficiency in cartilage in a surgically induced mouse model of osteoarthritis.
|
29323130 |
2018 |
Chronic small plaque psoriasis
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Tofacitinib was superior to placebo for the treatment of moderate-to-severe plaque psoriasis in the OPT Pivotal 1 and 2, OPT Retreatment studies, but FDA approval was declined for this indication based on issues of clinical efficacy and long-term safety.
|
30118353 |
2018 |
Posterior Vitreous Detachment
|
0.010 |
Biomarker
|
disease |
BEFREE |
Vitreous bodies identified to have posterior vitreous detachment were examined with phase-contrast microscopy and confocal microscopy after immunohistochemically staining for collagen IV basement membrane markers, in addition to extracellular proteins that characterize the vitreoretinal junction (fibronectin, laminin) and vitreous gel (opticin) markers.
|
28867131 |
2018 |
Heart failure
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Optimising pacemaker therapy and medical therapy in pacemaker patients for heart failure: protocol for the OPT-PACE randomised controlled trial.
|
31320354 |
2019 |
Congestive heart failure
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Optimising pacemaker therapy and medical therapy in pacemaker patients for heart failure: protocol for the OPT-PACE randomised controlled trial.
|
31320354 |
2019 |